Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 8/20 | 0.50 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14654132 | 0.91 | SORT1 (0.47) | SORT1LIPEEPAS1BTKALDH1A1 | |
| SCHEMBL14654097 | 0.90 | SORT1 (0.47) | SORT1LIPEEPAS1BTKGAA | |
| SCHEMBL25421609 | 0.88 | SORT1 (0.45) | SORT1LIPEEPAS1BTKGAA | |
| SCHEMBL29537527 | 0.87 | CA1 (0.47) | SORT1LIPEEPAS1BTKGRM5 | |
| SCHEMBL14630437 | 0.87 | CA1 (0.47) | SORT1LIPEEPAS1BTKGRM5 | |
| SCHEMBL18825302 | 0.87 | SORT1 (0.45) | SORT1LIPEEPAS1BTKGAA | |
| SCHEMBL60104 | 0.85 | KDR (0.47) | EPAS1GAAALDH1A1L3MBTL1BRAF | |
| SCHEMBL15878263 | 0.83 | LIPE (0.48) | SORT1LIPEEPAS1BTKGAA | |
| SCHEMBL15877976 | 0.83 | SORT1 (0.42) | SORT1LIPEEPAS1BTKGAA | |
| SCHEMBL15878544 | 0.82 | BTK (0.40) | SORT1LIPEBTKBRAFGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2948458-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481682-B2 | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353570-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014114185-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014113932-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
| US-20140206681-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206681-A1 | BTK INHIBITORS | BTK, SYK, LYN | SORT1 4460/4885LIPE 3810/4885EPAS1 3656/4885 |
| US-20150353570-A1 | BTK INHIBITORS | BTK, SYK, LYN | SORT1 4460/4885LIPE 3810/4885EPAS1 3656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.